Subrata K Ghosh1, Pamela Pantazopoulos, Zdravka Medarova, Anna Moore. 1. Molecular Imaging Laboratory, MGH/HST Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital/Harvard Medical School, Boston, MA 02129, USA.
Abstract
INTRODUCTION: Mucin 1 antigen (MUC1) is a high-molecular-weight transmembrane glycoprotein with an aberrant expression profile in various malignancies, including breast cancer. Its increased overexpression and underglycosylation in breast cancer is associated with tumor invasiveness and metastatic potential. In this study, we took the next step toward establishing MUC1 as a potential diagnostic, prognostic, and therapeutic target by investigating its expression and posttranslational modification (glycosylation/sialylation). PATIENTS AND METHODS: In these studies we used a breast cancer tissue microarray (TMA) and fresh-frozen multistage breast cancer tissues. We analyzed in detail the expression of normal and underglycosylated/sialated MUC1 by immunohistochemical techniques, real-time quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR), and various analytic techniques. RESULTS: We found that changes in cellular localization as well as in upregulation and/or underglycosylation of MUC1 were associated with higher tumor grade. A key finding in this study was that underglycosylated MUC1 (uMUC1) overexpression and sialation were observed in tissues adjacent to tumor but identified as normal on pathology reports. CONCLUSIONS: These findings suggest that uMUC1 can indeed be used as an early diagnostic marker and provide additional insights into breast cancer management.
INTRODUCTION:Mucin 1 antigen (MUC1) is a high-molecular-weight transmembrane glycoprotein with an aberrant expression profile in various malignancies, including breast cancer. Its increased overexpression and underglycosylation in breast cancer is associated with tumor invasiveness and metastatic potential. In this study, we took the next step toward establishing MUC1 as a potential diagnostic, prognostic, and therapeutic target by investigating its expression and posttranslational modification (glycosylation/sialylation). PATIENTS AND METHODS: In these studies we used a breast cancer tissue microarray (TMA) and fresh-frozen multistage breast cancer tissues. We analyzed in detail the expression of normal and underglycosylated/sialated MUC1 by immunohistochemical techniques, real-time quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR), and various analytic techniques. RESULTS: We found that changes in cellular localization as well as in upregulation and/or underglycosylation of MUC1 were associated with higher tumor grade. A key finding in this study was that underglycosylated MUC1 (uMUC1) overexpression and sialation were observed in tissues adjacent to tumor but identified as normal on pathology reports. CONCLUSIONS: These findings suggest that uMUC1 can indeed be used as an early diagnostic marker and provide additional insights into breast cancer management.
Authors: C D Hough; C A Sherman-Baust; E S Pizer; F J Montz; D D Im; N B Rosenshein; K R Cho; G J Riggins; P J Morin Journal: Cancer Res Date: 2000-11-15 Impact factor: 12.701
Authors: P Brossart; A Schneider; P Dill; T Schammann; F Grünebach; S Wirths; L Kanz; H J Bühring; W Brugger Journal: Cancer Res Date: 2001-09-15 Impact factor: 12.701
Authors: J Burchell; R Poulsom; A Hanby; C Whitehouse; L Cooper; H Clausen; D Miles; J Taylor-Papadimitriou Journal: Glycobiology Date: 1999-12 Impact factor: 4.313
Authors: V G Dyomin; N Palanisamy; K O Lloyd; K Dyomina; S C Jhanwar; J Houldsworth; R S Chaganti Journal: Blood Date: 2000-04-15 Impact factor: 22.113
Authors: Brigitte Rack; Julia Jückstock; Elisabeth Trapp; Tobias Weissenbacher; Marianna Alunni-Fabbroni; Amelie Schramm; Peter Widschwendter; Krisztian Lato; Thomas Zwingers; Ralf Lorenz; Hans Tesch; Andreas Schneeweiss; Peter Fasching; Sven Mahner; Matthias W Beckmann; Werner Lichtenegger; Wolfgang Janni Journal: Tumour Biol Date: 2016-08-01
Authors: Sarah A Flowers; Liaqat Ali; Catherine S Lane; Magnus Olin; Niclas G Karlsson Journal: Mol Cell Proteomics Date: 2013-03-01 Impact factor: 5.911
Authors: Ping Wang; Byunghee Yoo; Sarah Sherman; Pinku Mukherjee; Alana Ross; Pamela Pantazopoulos; Victoria Petkova; Christian Farrar; Zdravka Medarova; Anna Moore Journal: Int J Cancer Date: 2016-04-15 Impact factor: 7.396
Authors: Rajendra P Pangeni; Prasanna Channathodiyil; David S Huen; Lawrence W Eagles; Balraj K Johal; Dawar Pasha; Natasa Hadjistephanou; Oliver Nevell; Claire L Davies; Ayobami I Adewumi; Hamida Khanom; Ikroop S Samra; Vanessa C Buzatto; Preethi Chandrasekaran; Thoraia Shinawi; Timothy P Dawson; Katherine M Ashton; Charles Davis; Andrew R Brodbelt; Michael D Jenkinson; Ivan Bièche; Farida Latif; John L Darling; Tracy J Warr; Mark R Morris Journal: Clin Epigenetics Date: 2015-05-27 Impact factor: 6.551